Dr. Shi Li, MD, is a tuberculosis specialist with 8 years of clinical and research experience at a tertiary general hospital in China. Skilled in managing severe, drug-resistant, and comorbid tuberculosis, she actively participates in multicenter clinical trials to optimize treatment protocols for drug-resistant TB. Passionate about translational research, Dr. Shi focuses on bridging diagnostic challenges and therapeutic innovations to improve outcomes in high-burden populations.
A retrospective study from a TB-endemic region found that concurrent intestinal tuberculosis and colorectal cancer present with overlapping symptoms and histopathological complexities, highlighting the need for heightened clinical suspicion, endoscopic-histopathological integration, and multidisciplinary strategies combining anti-tuberculosis and oncological interventions to optimize outcomes in dual-pathology cases.
Source: Conference 2024tNGS significantly improves diagnostic yield and speed for MTBC/NTM while enabling comprehensive resistance profiling. Its ability to detect co-infections and rare resistance mutations addresses critical gaps in conventional algorithms. Multicenter prospective studies are warranted to standardize tNGS implementation in TB diagnostic pathways.
Source: Conference 2024